ArticleFrontiers in immunology2025
Bibliometric analysis and visualization of Connexin 43 in the field of solid tumor research(2000-2024).
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring research trends in cancer immunotherapy via single-cell technologies: a scientometric perspective.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Connexin 43 (Cx43) plays a pivotal role in tumor growth, metastasis, and disease progression. This study employs bibliometric analysis to identify key research trends and emerging hotspots in Cx43-related solid tumor research. Methods: In December 2024, the Web of Science Core Collection (WoSCC) database was searched for publications on Cx43 in solid tumor research from 2000 to 2024. Bibliometric analysis and data visualization were primarily conducted using CiteSpace, VOSviewer, and Bibliometrix, with a focus on visualizing aspects such as countries, institutions, journals, authors, references, and keywords in the field. Results: A total of 1,666 publications were retrieved, with the annual number of articles and citations continuing to grow. The United States and China had the highest number of publications, while the University of Western Ontario in Canada was the leading institution, with the most publications by Christian C.G. Nau. Lampe, P.D. was the most cited author. The International Journal of Molecular Sciences was the most frequently published journal, and the Journal of Biological Chemistry was the most frequently co-cited journal. High-frequency keywords included phosphorylation, breast cancer, gastric cancer, prognostic markers, anti-tumor immune response, and drug resistance. Conclusion: Contemporary research focuses on the role of Cx43 phosphorylation in tumorigenesis, progression, and metastasis, its potential as a prognostic biomarker, and its critical role as an immunotherapeutic target and in tumor drug resistance. These studies provide a comprehensive analysis for a deeper understanding of the role of Cx43 in solid tumors and help to promote further research in this area.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.